NASDAQ:FTH Sensei Biotherapeutics (FTH) Stock Price, News & Analysis $11.61 -1.74 (-13.03%) As of 01:06 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sensei Biotherapeutics Stock (NASDAQ:FTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sensei Biotherapeutics alerts:Sign Up Key Stats Today's Range$11.51▼$13.1750-Day Range$12.68▼$40.0552-Week Range$7.45▼$42.14Volume305,463 shsAverage Volume281,827 shsMarket Capitalization$300.05 millionP/E RatioN/ADividend YieldN/APrice Target$56.58Consensus RatingModerate Buy Company Overview Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body’s immune system recognize and attack cancer cells. The company’s publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products. Based in the United States, Sensei has focused its work on oncology research and development. Its approach has included developing antibody-based medicines and other immunotherapies for potential use alone or alongside existing cancer treatments.AI Generated. May Contain Errors. Read More Sensei Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreFTH MarketRank™: 2.942370661425 of 5 starsSensei Biotherapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 402nd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingSensei Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 2 strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSensei Biotherapeutics has a consensus price target of $56.58, representing about 369.5% upside from its current price of $12.05.Amount of Analyst CoverageSensei Biotherapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sensei Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sensei Biotherapeutics are expected to grow in the coming year, from ($13.35) to ($3.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sensei Biotherapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sensei Biotherapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSensei Biotherapeutics has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.36% of the float of Sensei Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSensei Biotherapeutics has a short interest ratio ("days to cover") of 6.31.Change versus previous monthShort interest in Sensei Biotherapeutics has recently increased by 17.67%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSensei Biotherapeutics does not currently pay a dividend.Dividend GrowthSensei Biotherapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment1.01 News SentimentSensei Biotherapeutics has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Sensei Biotherapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for FTH on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sensei Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sensei Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.00% of the stock of Sensei Biotherapeutics is held by insiders.Percentage Held by Institutions10.50% of the stock of Sensei Biotherapeutics is held by institutions.Read more about Sensei Biotherapeutics' insider trading history. Receive FTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FTH Stock News HeadlinesFaeth Therapeutics to Participate in Upcoming November Investor ConferencesNovember 11 at 7:30 AM | businesswire.comFaeth Therapeutics plummets 45% — here's what happenedNovember 10 at 5:54 PM | msn.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 12 at 1:00 AM | Weiss Ratings (Ad)Analyst Firms Have Faith In Faeth TherapeuticsNovember 5, 2026 | seekingalpha.comFaeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational UpdatesNovember 3, 2026 | businesswire.comFaeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against GedatolisibOctober 23, 2026 | businesswire.comFaeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026October 19, 2026 | businesswire.comFaeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug ExpansionSeptember 18, 2026 | seekingalpha.comSee More Headlines FTH Stock Analysis - Frequently Asked Questions How have FTH shares performed this year? Sensei Biotherapeutics' stock was trading at $16.65 on June 17, 2026. Since then, FTH shares have decreased by 27.6% and is now trading at $12.0530. How were Sensei Biotherapeutics' earnings last quarter? Sensei Biotherapeutics, Inc. (NASDAQ:FTH) posted its quarterly earnings results on Tuesday, November, 3rd. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by $0.13. When did Sensei Biotherapeutics' stock split? Sensei Biotherapeutics's stock reverse split on Tuesday, June 17th 2025.The 1-20 reverse split was announced on Friday, June 13th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Sensei Biotherapeutics' major shareholders? Sensei Biotherapeutics' top institutional shareholders include Candriam S.C.A. (1.24%), State Street Corp (1.21%), China Universal Asset Management Co. Ltd. (0.02%) and State of Wyoming. Insiders that own company stock include Anand Kiran Parikh, Millennium Management Llc and James Peyer. View institutional ownership trends. How do I buy shares of Sensei Biotherapeutics? Shares of FTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sensei Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sensei Biotherapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Micron Technology (MU), PayPal (PYPL), Nektar Therapeutics (NKTR), Advanced Micro Devices (AMD) and Walt Disney (DIS). Company Calendar Last Earnings11/03/2026Today11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 3 days ago, FTH's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:FTH Previous SymbolNASDAQ:SNSE CIK1829802 Webwww.faeththerapeutics.com Phone(512) 200-2982FaxN/AEmployees29Year Founded1999Price Target and Rating Average Price Target for Sensei Biotherapeutics$56.58 High Price Target$69.00 Low Price Target$50.00 Potential Upside/Downside+382.0%Consensus RatingModerate Buy Rating Score (0-4)2.94 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($138.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.08 million Net MarginsN/A Pretax MarginN/A Return on Equity-392.57% Return on Assets-141.72% Debt Debt-to-Equity RatioN/A Current Ratio16.12 Quick Ratio16.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.23 per share Price / Book1.88Miscellaneous Outstanding Shares25,844,000Free Float24,035,000Market Cap$303.41 million OptionableOptionable Beta-0.15 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:FTH) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of A...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
